1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 RESIDUE ALA 8 IS A D-ALANINE. Fesik, S.W. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C4 H9 N O2 103.120 n ALPHA-AMINOBUTYRIC ACID L-peptide linking C3 H7 N O2 89.093 y ALANINE L-peptide linking C10 H19 N O3 201.263 n 4-METHYL-4-[(E)-2-BUTENYL]-4,N-METHYL-THREONINE L-peptide linking C3 H7 N O2 89.093 D-ALANINE D-peptide linking C7 H15 N O2 145.199 n N-METHYLLEUCINE L-peptide linking C6 H13 N O2 131.173 n N-METHYLVALINE L-peptide linking C3 H7 N O2 89.093 n SARCOSINE peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US Biochemistry BICHAW 0033 0006-2960 30 6574 10.1021/BI00240A030 2054356 NMR Studies of [U-13C]Cyclosporin a Bound to Cyclophilin: Bound Conformation and Portions of Cyclosporin Involved in Binding. 1991 US J.Am.Chem.Soc. JACSAT 0004 0002-7863 113 7080 10.1021/JA00018A080 Identification of Solvent-Exposed Regions of Enzyme-Bound Ligands by Nuclear Magnetic Resonance 1991 NE FEBS Lett. FEBLAL 0165 0014-5793 294 81 10.1016/0014-5793(91)81348-C 1H, 13C and 15N Backbone Assignments of Cyclophilin When Bound to Cyclosporin a (Csa) and Preliminary Structural Characterization of the Csa Binding Site 1991 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 1220.625 CYCLOSPORIN A 1 syn polymer CYCLOSPORINE, CICLOSPORIN, CICLOSPORINE no yes (DAL)(MLE)(MLE)(MVA)(BMT)(ABA)(SAR)(MLE)V(MLE)A ALLVTAGLVLA A polypeptide(L) n n n n n n n n n n n repository Initial release Version format compliance Version format compliance Atomic model Database references Derived calculations Non-polymer description Structure summary Other 1 0 1994-01-31 1 1 2011-06-14 1 2 2011-07-13 1 3 2011-07-27 1 4 2012-12-12 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN C CRYSTAL STRUCTURE OF THE CYCLOPHILIN-LIKE DOMAIN FROM BRUGIA MALAYI COMPLEXED WITH CYCLOSPORIN A SOLUTION STRUCTURE OF E.COLI CYCLOPHILIN (F112W) COMPLEXED WITH CYCLOSPORIN A CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN A CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED CYCLOSPORIN A AT POSITION 5 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED CYCLOSPORIN A AT POSITION 8 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN D CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN A MODIFIED AT POSITION 7 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED CYCLOSPORIN D AT POSITION 7 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED CYCLOSPORIN D AT POSITIONS 5 AND 7. CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED CYCLOSPORIN D AT POSITIONS 5 AND 7. CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED CYCLOSPORIN A AT POSITION 8 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED CYCLOSPORIN A AT POSITION 8 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH NODIFIED CYCLOSPORIN C AT POSITIONS 1, AND 9 SOLUTION STRUCTURE OF HUMAN CYCLOPHILIN COMPLEXED WITH CYCLOSPORIN A CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN B COMPLEXED WITH MODIFIED CYCLOSPORIN A CRYSTAL STRUCTURE OF CTCLOSPORIN-FAB COMPLEX CRYSTAL STRUCTURE OF CALCINEURIN-CYCLOPHILIN-CYCLOSPORIN COMPLEX CRYSTAL STRUCTURE OF HUMAN CALCINEURIN COMPLEXED WITH HUMAN CYCLOPHILIN AND CYCLOSPORIN A CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED CYCLOSPORIN A AT POSITION 6 CRYSTAL STRUCTURE OF PLASMODIUM FALCIPARUM CYCLOPHILIN COMPLEXED WITH CYCLOSPORIN A CRYSTAL STRUCTURE OF PLASMODIUM FALCIPARUM CYCLOPHILIN (DOUBLE MUTANT) COMPLEXED WITH CYCLOSPORIN A CRYSTAL STRUCTURE OF TRYPANOSOMA CRUZI CYCLOPHILIN COMPLEXED WITH CYCLOSPORIN A CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN C COMPLEXED WITH CYCLOSPORIN A CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN J COMPLEXED WITH CYCLOSPORIN A CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM IOWA II CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN A CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN A CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED CYCLOSPORIN A AT POSITION 5 CRYSTAL STRUCTURE OF MURINE CYCLOPHILIN C COMPLEXED WITH CYCLOSPORIN A CRYSTAL STRUCTURE OF THE PPIASE DOMAIN OF HUMAN CYCLOPHILIN G COMPLEXED WITH CYCLOSPORIN A CRYSTAL STRUCTURE OF HUMAN ACETYL-CYPA COMPLEXED WITH CYCLOSPORINE A CRYSTAL STRUCTURE OF PPIL1 COMPLEXED WITH CYCLOSPORINE A CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN D IN COMPLEX WITH CYCLOSPORIN A CRYSTAL STRUCTURE OF CYCLOSPHILIN A FROM TOXOPLASMA GONDII COMPLEXED WIT CYCLOSPORIN A SOLUTION STRUCTURE OF THE HUMAN CYCLOSPORIN A COMPLEXED WITH CYCLOSPORIN A CRYSTAL STRUCTURE OF CYCLOPHILIN FROM LEISHMANIA DONOVANI COMPLEXED WITH CYCLOSPORIN A Y 1992-02-24 REL 29910 TOLYPOCLADIUM INFLATUM sample CYCLOSPORIN IS A CYCLIC UNDECAPEPTIDE. HERE, CYCLOSPORIN A IS REPRESENTED BY THE SEQUENCE (SEQRES) Immunosuppressant CYCLOSPORIN IS A CYCLIC UNDECAPEPTIDE. CYCLIZATION IS ACHIEVED BY LINKING THE N- AND THE C- TERMINI. Cyclosporin A Cyclic peptide 20 HARE RESEARCH INC. (DSPACE), BRUNGER (X-PLOR) refinement DSPACE, X-PLOR DAL 1 n 1 DAL 1 A MLE 2 n 2 MLE 2 A MLE 3 n 3 MLE 3 A MVA 4 n 4 MVA 4 A BMT 5 n 5 BMT 5 A ABA 6 n 6 ABA 6 A SAR 7 n 7 SAR 7 A MLE 8 n 8 MLE 8 A VAL 9 n 9 VAL 9 A MLE 10 n 10 MLE 10 A ALA 11 n 11 ALA 11 A author_defined_assembly 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 1 A A BMT ABA 5 6 134.10 1 A A ABA SAR 6 7 104.74 1 A A SAR MLE 7 8 113.87 2 A A MLE MVA 3 4 149.05 2 A A BMT ABA 5 6 -131.98 2 A A ABA SAR 6 7 -97.85 2 A A SAR MLE 7 8 -141.91 3 A A DAL MLE 1 2 145.90 3 A A MLE MLE 2 3 -140.51 3 A A BMT ABA 5 6 -98.20 3 A A ABA SAR 6 7 -117.89 3 A A SAR MLE 7 8 -105.22 4 A A DAL MLE 1 2 142.81 4 A A MLE MLE 2 3 -148.82 4 A A BMT ABA 5 6 -148.29 4 A A ABA SAR 6 7 -84.77 4 A A SAR MLE 7 8 96.83 5 A A MLE MLE 2 3 -148.86 5 A A MLE MVA 3 4 141.02 5 A A BMT ABA 5 6 -132.24 5 A A ABA SAR 6 7 -117.97 5 A A SAR MLE 7 8 -126.67 6 A A MLE MLE 2 3 -147.56 6 A A MLE MVA 3 4 149.11 6 A A BMT ABA 5 6 -148.26 6 A A ABA SAR 6 7 -110.90 6 A A SAR MLE 7 8 -136.75 7 A A MLE MLE 2 3 -148.96 7 A A MLE MVA 3 4 149.87 7 A A BMT ABA 5 6 -138.77 7 A A ABA SAR 6 7 -132.52 7 A A SAR MLE 7 8 -85.28 8 A A MLE MLE 2 3 -147.29 8 A A BMT ABA 5 6 -131.29 8 A A ABA SAR 6 7 -144.35 9 A A MLE MLE 2 3 -145.91 9 A A ABA SAR 6 7 -118.33 9 A A SAR MLE 7 8 78.80 10 A A BMT ABA 5 6 111.38 10 A A SAR MLE 7 8 -140.74 10 A A MLE VAL 8 9 -144.50 11 A A DAL MLE 1 2 139.22 11 A A MLE MLE 2 3 -141.49 11 A A MLE MVA 3 4 147.14 11 A A BMT ABA 5 6 134.89 11 A A ABA SAR 6 7 -145.38 11 A A SAR MLE 7 8 -103.79 11 A A MLE VAL 8 9 -143.41 12 A A DAL MLE 1 2 137.33 12 A A MLE MLE 2 3 -143.32 12 A A BMT ABA 5 6 -130.66 12 A A ABA SAR 6 7 -124.06 12 A A SAR MLE 7 8 -78.16 12 A A MLE VAL 8 9 -149.46 13 A A MLE MLE 2 3 -146.56 13 A A BMT ABA 5 6 145.64 13 A A ABA SAR 6 7 -107.15 13 A A SAR MLE 7 8 98.95 14 A A MLE MLE 2 3 -146.56 14 A A ABA SAR 6 7 -74.89 14 A A SAR MLE 7 8 103.50 15 A A MLE MLE 2 3 -143.80 15 A A ABA SAR 6 7 -87.70 15 A A SAR MLE 7 8 75.19 15 A A MLE ALA 10 11 146.42 16 A A MLE MVA 3 4 148.27 16 A A BMT ABA 5 6 -133.38 16 A A ABA SAR 6 7 -108.04 16 A A SAR MLE 7 8 -133.39 17 A A SAR MLE 7 8 50.34 18 A A MLE MLE 2 3 -148.43 18 A A MLE MVA 3 4 144.58 18 A A BMT ABA 5 6 -120.54 18 A A ABA SAR 6 7 -99.99 18 A A SAR MLE 7 8 116.38 18 A A MLE ALA 10 11 147.15 19 A A MLE MLE 2 3 -148.51 19 A A ABA SAR 6 7 -103.05 19 A A SAR MLE 7 8 84.61 20 A A MLE MLE 2 3 -140.54 20 A A BMT ABA 5 6 -127.79 20 A A ABA SAR 6 7 -127.32 20 A A SAR MLE 7 8 -89.71 20 A A MLE ALA 10 11 122.21 2 A BMT 5 -117.43 -169.44 2 A ABA 6 -164.69 46.02 3 A BMT 5 -123.07 -167.58 3 A ABA 6 -141.35 47.35 4 A MLE 3 -65.26 -178.54 4 A ABA 6 -155.75 65.36 5 A MLE 3 -66.45 -175.50 5 A BMT 5 -126.61 -167.30 5 A ABA 6 -154.15 57.27 6 A ABA 6 -100.74 76.07 7 A BMT 5 -116.33 -163.99 7 A ABA 6 -150.84 72.50 8 A ABA 6 -142.60 49.98 9 A MLE 2 -107.74 47.01 10 A ABA 6 35.17 40.52 11 A MLE 3 -67.29 -177.41 12 A MLE 3 -68.93 -172.97 12 A ABA 6 -113.78 59.27 13 A MLE 2 -108.20 53.85 13 A MLE 10 -105.60 -168.49 14 A MLE 10 -101.01 -169.27 16 A MLE 2 -112.59 60.43 17 A ABA 6 55.00 175.38 17 A MLE 8 -115.26 72.86 18 A MLE 2 -109.66 49.01 18 A BMT 5 -131.39 -155.78 18 A ABA 6 -174.71 36.23 model building X-PLOR refinement X-PLOR phasing X-PLOR CYCLOSPORIN A NMR STUDIES OF (U-13C)CYCLOSPORIN A BOUND TO CYCLOPHILIN: BOUND CONFORMATION AND PORTIONS OF CYCLOSPORIN INVOLVED IN BINDING 1 N N covale 1.307 A DAL 1 A N DAL 1 1_555 A ALA 11 A C ALA 11 1_555 covale 1.319 A DAL 1 A C DAL 1 1_555 A MLE 2 A N MLE 2 1_555 covale 1.310 A MLE 2 A C MLE 2 1_555 A MLE 3 A N MLE 3 1_555 covale 1.311 A MLE 3 A C MLE 3 1_555 A MVA 4 A N MVA 4 1_555 covale 1.321 A MVA 4 A C MVA 4 1_555 A BMT 5 A N BMT 5 1_555 covale 1.307 A BMT 5 A C BMT 5 1_555 A ABA 6 A N ABA 6 1_555 covale 1.312 A ABA 6 A C ABA 6 1_555 A SAR 7 A N SAR 7 1_555 covale 1.314 A SAR 7 A C SAR 7 1_555 A MLE 8 A N MLE 8 1_555 covale 1.310 A MLE 8 A C MLE 8 1_555 A VAL 9 A N VAL 9 1_555 covale 1.317 A VAL 9 A C VAL 9 1_555 A MLE 10 A N MLE 10 1_555 covale 1.305 A MLE 10 A C MLE 10 1_555 A ALA 11 A N ALA 11 1_555 IMMUNOSUPPRESSANT IMMUNOSUPPRESSANT, CYCLOSPORIN A NOR00033 NOR 1 NOR00033 1 11 1CYB 1 11 NOR00033 A 1 1 11 1 P 1